Altimmune Beats Earnings, But Stock Slides 6%

Financial Performance and Liquidity Position

Altimmune Inc. reported its second-quarter 2026 financial results on September 10, 2026, demonstrating improved operational efficiency despite continued net losses. The company posted a loss of $0.12 per share, outperforming the consensus estimate of $0.15 per share by 20%. While the per-share loss narrowed, the net loss widened to $22.8 million from $22.1 million year-over-year, driven by increased operational expenditures.

Research and development expenses increased by 8.7% to $18.7 million, reflecting ongoing investment in clinical trials. General and administrative costs saw a sharper rise, jumping 33.3% to $7.6 million. These figures contrast with the company’s robust balance sheet. Altimmune holds $519 million in cash, having raised $310 million year-to-date, which includes a $225 million offering in April. Management confirmed that this liquidity runway extends through the readout of the MASH trial in 2029, providing substantial capital to support late-stage development without immediate dilution concerns.

Clinical Pipeline Progress

The company’s clinical pipeline advanced significantly during the quarter, marking critical milestones for its lead assets. The Phase II RECLAIM study for alcohol use disorder successfully met its primary endpoint. Following this positive outcome, Altimmune plans to initiate a pre-Phase III meeting with the FDA to discuss the path forward toward Phase III development. The company is actively seeking non-dilutive funding to support the next stage of this program.

In the metabolic-associated steatohepatitis (MASH) space, the Phase III PERFORMA trial continues to enroll patients across 290 to 300 global sites. The enrollment target for this study is set between 18 and 24 months. Additionally, data from the Phase III ALD study, RESTORE, is expected to be released in the second half of 2027. These developments underscore the company’s strategic focus on advancing its infectious disease and metabolic disease franchises through late-stage clinical evaluation.

Analyst Sentiment and Market Outlook

Market analysts have maintained a predominantly bullish stance on Altimmune following the earnings release. Several major institutions have reiterated their buy ratings, citing the company’s strong cash position and promising clinical data. H.C. Wainwright maintained a buy rating with a price target of $20, representing significant upside potential. Similarly, Citizens maintained a buy rating with a target of $11, while Leerink initiated coverage with a buy rating and a target of $10.

Other firms, including Evercore ISI and Jefferies, also maintained buy ratings with price targets of $22 and $28, respectively. Goldman Sachs upgraded its rating to hold with a target of $2.5, reflecting a more conservative view. The consensus among analysts projects substantial value appreciation, with targets ranging from $2.5 to $28. This divergence highlights varying perspectives on the timeline to profitability and the risk profile of clinical trials. However, the prevailing analyst view emphasizes the company’s financial stability and the strategic importance of its upcoming clinical readouts.

Market Reaction

Despite the positive earnings beat and clinical progress, the stock experienced a modest decline in the short term. On September 11, 2026, ALT rose by 1.44% within 24 hours to reach $0.006119. However, the stock dropped by 6.53% over the past seven days, by 0.02% over the past month, and by 46.44% over the past year. This volatility reflects the market’s broader assessment of the company’s long-term trajectory and the inherent risks associated with biopharmaceutical development. Investors are closely monitoring the upcoming FDA meetings and trial enrollments to gauge the near-term direction of the stock.